Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2018 2
2019 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM. Schalkwijk S, et al. J Antimicrob Chemother. 2019 May 1;74(5):1348-1356. doi: 10.1093/jac/dky567. J Antimicrob Chemother. 2019. PMID: 30715324 Free PMC article.
OBJECTIVES: To evaluate total and unbound darunavir exposures following standard darunavir/ritonavir dosing and to explore the value of potential optimized darunavir/ritonavir dosing regimens for HIV-positive pregnant women. ...Unbound darunavir AUC0-t …
OBJECTIVES: To evaluate total and unbound darunavir exposures following standard darunavir/ritonavir dosing and to explore the …
Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Colbers A, Greupink R, Litjens C, Burger D, Russel FG. Colbers A, et al. Clin Pharmacokinet. 2016 Mar;55(3):381-96. doi: 10.1007/s40262-015-0325-8. Clin Pharmacokinet. 2016. PMID: 26369773 Free PMC article.
Here, we used mechanistic modelling to delineate the potential impact of drug transporters on darunavir pharmacokinetics and to identify current knowledge gaps that limit accurate PBPK modelling of darunavir/ritonavir (darunavir/r) exposure in pregnancy. ...I …
Here, we used mechanistic modelling to delineate the potential impact of drug transporters on darunavir pharmacokinetics and to ident …
Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
Colbers A, Moltó J, Ivanovic J, Kabeya K, Hawkins D, Gingelmaier A, Taylor G, Weizsäcker K, Sadiq ST, Van der Ende M, Giaquinto C, Burger D; PANNA Network. Colbers A, et al. J Antimicrob Chemother. 2015 Feb;70(2):534-42. doi: 10.1093/jac/dku400. Epub 2014 Oct 17. J Antimicrob Chemother. 2015. PMID: 25326090 Clinical Trial.
All children were tested HIV-negative and no congenital abnormalities were reported. CONCLUSIONS: Darunavir AUC and Cmax were substantially decreased in pregnancy for both darunavir/ritonavir regimens. This decrease in exposure did not result in mother-to-child tran …
All children were tested HIV-negative and no congenital abnormalities were reported. CONCLUSIONS: Darunavir AUC and Cmax were substan …
Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger DM, Greupink R, Russel FGM. Schalkwijk S, et al. Clin Pharmacokinet. 2018 Jun;57(6):705-716. doi: 10.1007/s40262-017-0583-8. Clin Pharmacokinet. 2018. PMID: 28744795 Free PMC article.
OBJECTIVE: The aim of this study was to incorporate placental transfer into a pregnancy physiologically based pharmacokinetic model to simulate and evaluate fetal darunavir exposure at term. METHODS: An existing and validated pregnancy physiologically based pharmacokinetic …
OBJECTIVE: The aim of this study was to incorporate placental transfer into a pregnancy physiologically based pharmacokinetic model to simul …
Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
Bastiaans DET, Geelen SPM, Visser EG, van der Flier M, Vermont CL, Colbers APH, Roukens M, Burger DM, van Rossum AMC; Dutch Paediatric HIV Study Group. Bastiaans DET, et al. Pediatr Infect Dis J. 2018 Oct;37(10):1008-1010. doi: 10.1097/INF.0000000000001964. Pediatr Infect Dis J. 2018. PMID: 29474261
In this multicenter pharmacokinetic study in HIV-infected children (6-12 years of age), we validated the approved once-daily darunavir/ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 hmg/L, subst …
In this multicenter pharmacokinetic study in HIV-infected children (6-12 years of age), we validated the approved once-daily darunavir
Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus.
Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D. Colbers A, et al. Clin Infect Dis. 2019 Sep 13;69(7):1254-1258. doi: 10.1093/cid/ciz121. Clin Infect Dis. 2019. PMID: 30783649 Free PMC article.
Recently, the US Food and Drug Administration and European Medicines Agency issued warnings on the use of dolutegravir and darunavir/cobicistat for treatment of pregnant women living with human immunodeficiency virus (HIV). ...
Recently, the US Food and Drug Administration and European Medicines Agency issued warnings on the use of dolutegravir and darunavir/ …